Emergent BioSolutions (NYSE:EBS) Trading Down 5.7% – Here’s What Happened

Emergent BioSolutions Inc. (NYSE:EBS)’s stock price traded down 5.7% during mid-day trading on Tuesday . The company traded as low as $9.22 and last traded at $9.28. 499,409 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 3,266,502 shares. The stock had previously closed at $9.84.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark increased their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th.

Emergent BioSolutions Stock Down 5.8 %

The firm’s 50 day moving average is $9.18 and its two-hundred day moving average is $8.48. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a market cap of $502.29 million, a P/E ratio of -2.31 and a beta of 1.59.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC boosted its holdings in shares of Emergent BioSolutions by 32,706.7% during the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares during the period. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the second quarter valued at about $41,000. Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions during the second quarter worth $68,000. Stifel Financial Corp bought a new stake in Emergent BioSolutions during the 3rd quarter worth $96,000. Finally, FORA Capital LLC bought a new stake in shares of Emergent BioSolutions during the third quarter worth about $103,000. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.